Scienture Reports Preliminary Q3 Revenue Up 256% Sequentially to About $1.22 Million
Scienture said preliminary unaudited third-quarter revenue rose 256% sequentially to approximately $1.22 million, supported by Arbli growth and the commercial launch of REZENOPY. The company also highlighted two FDA-approved commercial products and progress toward profitability in 2027.
Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli™ Growth and the Commercial Launch of REZENOPY™Two FDA-Approved Commercial Products Position Company for Continued Sequential Revenue GrowthHigh Gross Margins and Esta…